Investor Relations Overview | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

At UCB,
we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 


 

Upcoming IR Events

Jefferies Structural Winners Conference

Virtual 1x1 meetings

Citi 11th Annual European Healthcare Conference

In-person meetings in London

UBS Bus Tour

In-person meeting in Paris


 

Guidance

Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges.

The figures of the guidance 2022 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2021. The financial guidance 2022 will be updated upon closing of the planned Zogenix, Inc. acquisition.

 

Upcoming Report

2022 Half-Year Results

More information closer to the date

Ellinghorst IR Consensus

2022 Revenue

€ 5.15 - 5.4 billion

based on continued core product growth and taking into account loss of exclusivity impacts

 

2022 adj. EBITDA 

26% - 27%

reflecting the continued high R&D and marketing & selling investment levels

 

2022 Core EPS

€ 4.80 - 5.30

based on an average of 189 million shares outstanding

 

2025 Revenue

at least € 6 billion

2025 adj. EBITDA

Low- to mid-thirties

2025 Improved ESG

rating performance


 

Contact UCB IR Team

investor-relations@ucb.com or a specific team member:

 

UCB IR App